Variants derived from ActRIIB and uses therefor

Details Variants derived from ActRIIB and uses therefor Variants derived from ActRIIB and uses therefor

2008-02-04

2010-11-30

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S007600, C514S008100, C530S350000, C530S402000, C435S069700

Reexamination Certificate

active

07842663

ABSTRACT:
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

REFERENCES:
patent: 4973577 (1990-11-01), Vale, Jr. et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5847078 (1998-12-01), Eto et al.
patent: 5885794 (1999-03-01), Mathews et al.
patent: 6093547 (2000-07-01), Jin et al.
patent: 6132988 (2000-10-01), Sugino et al.
patent: 6162896 (2000-12-01), Mathews et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6599876 (2003-07-01), Kojima
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7202210 (2007-04-01), Wolfman et al.
patent: 7560441 (2009-07-01), Wolfman et al.
patent: 2003/0083251 (2003-05-01), Westenfelder
patent: 2003/0118556 (2003-06-01), Kaspar et al.
patent: 2004/0197828 (2004-10-01), Gaddy
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0068468 (2006-03-01), Knopf et al.
patent: 2006/0210657 (2006-09-01), Chou
patent: 2007/0048830 (2007-03-01), Gilbert et al.
patent: 2007/0149455 (2007-06-01), Wolfman et al.
patent: 2007/0172956 (2007-07-01), Magari et al.
patent: 2007/0184052 (2007-08-01), Lin et al.
patent: 2007/0249022 (2007-10-01), Knopf et al.
patent: 2007/0275895 (2007-11-01), Duan et al.
patent: 2007/0292885 (2007-12-01), Bejanin et al.
patent: 2008/0021104 (2008-01-01), Tarallo
patent: 2008/0075692 (2008-03-01), Perrine
patent: 2008/0089897 (2008-04-01), Wolfman
patent: 2008/0139590 (2008-06-01), Qian et al.
patent: 2009/0005308 (2009-01-01), Knopf et al.
patent: 2009/0047281 (2009-02-01), Sherman
patent: 2009/0074768 (2009-03-01), Knopf et al.
patent: 2009/0087433 (2009-04-01), Wolfman et al.
patent: 2009/0098113 (2009-04-01), Knopf et al.
patent: 2009/0099086 (2009-04-01), Knopf et al.
patent: 2009/0118188 (2009-05-01), Knopf et al.
patent: 2009/0142333 (2009-06-01), Knopf et al.
patent: 2009/0163417 (2009-06-01), Sherman
patent: 1174149 (2002-01-01), None
patent: WO-92/20793 (1992-11-01), None
patent: WO-95/10611 (1995-04-01), None
patent: WO-99/06559 (1999-02-01), None
patent: WO-00/43781 (2000-07-01), None
patent: WO-02/10214 (2002-02-01), None
patent: WO-02/43759 (2002-06-01), None
patent: WO-02/085306 (2002-10-01), None
patent: WO-03/006057 (2003-01-01), None
patent: WO-03/072808 (2003-09-01), None
patent: WO-2004/039948 (2004-05-01), None
patent: WO-2004/108157 (2004-12-01), None
patent: WO-2005/009460 (2005-02-01), None
patent: WO-2005/028517 (2005-03-01), None
patent: WO-2005/094871 (2005-10-01), None
patent: WO-2005/097825 (2005-10-01), None
patent: WO-2006002387 (2006-01-01), None
patent: WO-2006/012627 (2006-02-01), None
patent: WO-2006020884 (2006-02-01), None
patent: WO-2006/039400 (2006-04-01), None
patent: WO-2006/083183 (2006-08-01), None
patent: WO-2006/088972 (2006-08-01), None
patent: WO-2007/053775 (2007-05-01), None
patent: WO-2007/062188 (2007-05-01), None
patent: WO-2007/067616 (2007-06-01), None
patent: WO-2008/031061 (2008-03-01), None
patent: WO-2008/060139 (2008-05-01), None
patent: WO-2008/076437 (2008-06-01), None
patent: WO-2008/097541 (2008-08-01), None
patent: WO-2008/100384 (2008-08-01), None
patent: WO-2008/109167 (2008-09-01), None
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 492-495.
Abaza, M.S.I., et al., “Effects of Amino acid Substitutions Outside an Antigenic Site,” J. Protein Chem., 11(5):433-444 (1992).
Bowie, J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 257:1306-1310 (1990).
Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” J. Cell Biol., 111:2129-2138 (1990).
Colman, P.M., et al., “Effects of amino acid sequence changes on antibody-antigen interactions,” Research of Immunology, 145(1):33-36 (1994).
Donaldson, C.J., et al., “Activin and inhibin binding to the soluble extracellular domain of activin receptor II”, Endocrinology 140(4):1760-1766 (1999).
Donaldson, C.J., et al., “Molecular Cloning and Binding Properties of the Human Type II Activin Receptor”, Biochemical and Biophysical Research Communications, 184(1):310-316 (1992).
Ge, G., et al., “GDF11 Forms a Bone Morphogenetic Protein 1-Activated Latent Complex That Can Modulate Nerve Growth Factor-Induced Differentiation of PC12 Cells”, Molecular and Cellular Biology, 25(14):5846-5858 (2005).
GenBank NM—001106,Homo sapiensactivin A receptor, type IIB (ACVR2B), mRNA, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=116734707 (Downloaded on Jan. 29, 2007).
Gonzalez-Cadavid, N.F., et al., “Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting,” PNAS, 95:14938-14943 (1998).
Greenspan, N.S., et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, 17:936-937 (1999).
Gura, T., “Cancer Models: Systems for Identifying New Drugs Are Often Faulty,” Science, 278(5340):1041-1042 (1997).
Hamrick, M.W., et al., “Femoral Morphology and Cross-sectional Geometry of Adult Myostatin-deficient Mice,” Bone, 27(3):343-349 (2000).
Hemmati-Brivanlou, A., et al., “A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos,” Nature, 359:609-614 (1992).
Herbert, W.J., et al., The Dictionary of Immunology, Academic Press, 3rd Edition, London, pp. 58-59 (1985).
Hilden, K., et al., “Expression of Type II Activin Receptor Genes During Differentiation of Human K562 Cells and cDNA Cloning of the Human Type IIB Activin Receptor,” Blood, 83(8):2163-2170 (1994).
Hill, J.J., et al., “Regulation of Myostatin in Vivo by Growth and Differentiation Factor-Associated Serum Protein-1: A Novel Protein with Protease Inhibitor and Follistatin Domains,” Molecular Endocrinology, 17(6):1144-1154 (2003).
Kaiser, J., “First Pass at Cancer Genome Reveals Complex Landscape,” Science, 313:1370 (2006).
Kaspar, B.K., et al., “Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model,” Science, 301:839-842 (2003).
Kosaki, R., et al., “Left-Right Axis Malformations Associated With Mutations inACVR2B, the Gene for Human Activin Receptor Type IIB,” American Journal of Medical Genetics, 82:70-76 (1999).
Lazar, E., et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, 8(3):1247-1252 (1988).
Lee, et al., “Regulation of Myostatin Activity and Muscle Growth,” PNAS, 98(16):9306-9311 (2001).
Matzuk et al., “Different phenotypes for mice deficient in either activins or activin receptor type II,” Nature, 374:356-360 (1995).
McNally, E.M., “Powerful Genes—Myostatin Regulation of Human Muscle Mass,” N. Engl. J. Med., 350(26):2642-2644 (2004).
McPherron, A.C., et al., “Regulation of Skeletal Muscle Mass in Mice by a Bew TGF-b Superfamily Member,” Nature, 387:83-90 (1997).
Oh, S.P., et al., “Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning,” Genes & Development, 16:2749-2754 (2002).
Rebb

Affiliated with

Also associated with

Rating

Variants derived from ActRIIB and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Variants derived from ActRIIB and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants derived from ActRIIB and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4196602